Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

RG Biopharma (United States) | Researchclopedia

Back to institutions

RG Biopharma (United States)

San Diego, Californiacompany

26

Works

1,311

Citations

20

h-index

Top Research Topics

Asthma and respiratory diseases Synthesis and biological activity Melanoma and MAPK Pathways

Top Researchers

Ling Li Qingdao University

922 works30,356 citationsh-index: 73

Recent Research

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies

Tadashi Manabe,Hannah C. Bergo,et al.

20260 citations

Glutathione Transferases and Polymorphisms

Dermatology and Skin Diseases

Ion channel regulation and function

Sphingolipid Metabolism and Signaling

Genomics, phytochemicals, and oxidative stress

Cytokine Signaling Pathways and Interactions

Phagocytosis and Immune Regulation

Parkinson's Disease Mechanisms and Treatments

Antibiotic Resistance in Bacteria

35 works15,590 citationsh-index: 18

Gloria Lee Florida State University

189 works15,573 citationsh-index: 59

Yun Liu Shenyang Pharmaceutical University

490 works10,965 citationsh-index: 45

Richard T. Williams Principia Biopharma (United States)

101 works9,984 citationsh-index: 37

Michael Hall Fox Chase Cancer Center

281 works9,221 citationsh-index: 41

Restricting Liafensine on the Basis of <i>ANK3</i> Genotype—More Evidence Needed—Reply

Gang Wang,Matthew A. Spear,et al.

20250 citations

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

Jonathan I. Silverberg,Emma Guttman‐Yassky,et al.

20250 citations

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies

Trever G. Bivona,Tadashi Manabe,et al.

20250 citations

ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression

G. Wang,Mario Aguado,et al.

20255 citations

Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized phase II trial (S <u>EASI</u> DE CHINA): initial 2-week dosing, followed by 2-week or 4-week dosing

Jianzhong Zhang,Jonathan I. Silverberg,et al.

20252 citations